Octapharma underlines strong commitment to haemophilia A patients with the publication of new clinical data on PK-guided personalized prophylaxis according to the NuPreviq Approach with Nuwiq®
Lachen, Switzerland, May 22nd 2017: Octapharma announces positive new clinical data in 66 previously treated patients (PTPs) with severe haemophilia A (HA) undergoing PK-guided personalized prophylaxis with Nuwiq® according to...
Octapharma USA Sponsors ‘Hope Ignites: Stories to Inspire’ Program at Hemophilia Federation of America Annual Symposium
HOBOKEN, N.J. (April 7, 2017) – Octapharma USA today sponsored the patient symposium “Hope Ignites: Stories to Inspire,” during the Hemophilia Federation of America (HFA) Annual Symposium in Providence, Rhode Island....
Octapharma Group publishes 2016 annual results reporting revenue of €1.6 billion and operating income of €383 million
Lachen, Switzerland, March 1st, 2017: The Octapharma Group can report a record-breaking result with sales of €1.6 billion, which represents an increase of €87 million or 5.8% compared with 2015. Octapharma achieved sales...